Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated September 21, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2026, which is part of a broader 12-month repurchase plan commencing February 4, 2026.
Key Financial Metrics and Capital Allocation
The filing focuses on capital return activities rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares between May 6, 2026, and February 1, 2027.
- Accumulated Repurchases (as of Sept 18, 2026): 34,174,179 B shares purchased since February 4, 2026.
- Total Value Repurchased (since Feb 4, 2026): DKK 9,629,922,935.
- Average Purchase Price: DKK 281.79 per B share.
- Treasury Shares Held: 48,214,876 B shares (1.1% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
Since the last announcement on September 14, 2026, the company executed five additional transactions between September 15 and September 18, 2026.
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Sept 15, 2026 | 210,000 | 281.51 | 59,116,680 |
| Sept 16, 2026 | 210,000 | 278.16 | 58,414,268 |
| Sept 17, 2026 | 220,000 | 276.33 | 60,792,079 |
| Sept 18, 2026 | 225,000 | 275.54 | 61,996,942 |
| Sept 18, 2026 | 225,000 | 281.85 | 63,416,489 |
The filing does not provide comparative financial data (revenue, profit, cash flow) for the prior period as this is a capital allocation report, not an earnings release.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period beginning February 4, 2026. As of September 18, 2026, approximately DKK 9.63 billion of the programme has been utilized.
Risks and Contingencies: The filing does not disclose new material risks or contingencies. It references compliance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules regarding the repurchase programme.
Unusual Items: None reported. The activity is consistent with the announced share buyback strategy.
Key Facts for Investor Verification
- Verify the remaining capacity of the DKK 15 billion share repurchase programme (approximately DKK 5.37 billion remaining as of Sept 18, 2026).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 281.79.
- Check the company's liquidity position to ensure the remaining buyback commitments do not impact operational cash flow or debt covenants.
- Review the total number of treasury shares (48.2 million) to assess potential dilution or future reissuance plans.